13F Holdings
中文EN

KMTS KESTRA MEDICAL TECHNOLOGIES, LTD.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1877184 · Fiscal year ends 04/30

Financial factors as of 2026-07-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY60.7%
TTM net income YoY-25.1%
TTM EPS YoY40.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin53.9%
Operating margin-134.5%
Net margin-140.4%
FCF margin-115.0%
EBITDA margin-125.7%

Returns

ROE-73.7%
ROA-48.8%
ROIC (approx.)-90.4%
Asset turnover0.35x

Leverage & solvency

Liabilities / assets36.0%
Debt / equity0.33x
Current ratio4.69x
Interest coverage-18.98x

Cash quality & payout

Operating cash flow / net income0.59x
Accruals ratio-20.3%
Payout ratio—
Capex / revenue32.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q12026-07-312026Q4*2026-04-302026Q32026-01-312025Q22025-10-312025Q12025-07-312025Q4*2025-04-302025Q32025-01-312025Q22024-10-31
Income statement
Revenue$30.97M$28.64M$24.55M$22.57M$19.37M$17.23M$15.09M$14.71M
Cost of revenue$13.47M$12.96M$11.65M$11.14M$10.52M$9.60M$8.54M$8.88M
Gross profit$17.50M$15.68M$12.91M$11.42M$8.85M$7.63M$6.55M$5.83M
R&D expense$6.80M$5.63M$4.97M$4.88M$4.00M$5.39M$3.35M$3.51M
SG&A expense$48.36M$49.39M$42.70M$38.30M$33.73M$50.46M$23.80M$21.45M
Operating income-$37.66M-$39.34M-$34.77M-$31.75M-$28.88M-$48.21M-$20.60M-$19.13M
Interest expense$1.93M$1.84M$1.89M$1.90M$1.91M$1.76M$1.78M$2.32M
Pretax income-$44.04M-$38.64M-$34.13M-$32.75M-$25.79M-$51.01M-$21.74M-$20.61M
Income tax$50,000$192,000$35,000$34,000$33,000$102,000$18,000$8,000
Net income-$44.09M-$38.84M-$34.17M-$32.78M-$25.83M-$52.05M-$21.51M-$20.37M
EBITDA-$34.99M-$37.02M-$32.78M-$29.38M-$26.85M-$46.38M-$18.71M-$17.27M
EPS (basic)-0.75—-0.61-0.64-0.50—-1.25-1.19
EPS (diluted)-0.75—-0.61-0.64-0.50—-1.25-1.19
Weighted avg. shares (diluted)58.57M—55.85M51.38M51.30M—19.89M19.89M
Balance sheet
Cash & equivalents$68.56M$99.71M$291.32M$175.42M$201.21M$237.93M$54.35M$76.92M
Short-term investments$130.35M$96.72M——————
Receivables$15.41M$14.54M$12.71M$10.41M$9.25M$8.08M——
Current assets$226.27M$222.36M$314.06M$195.41M$220.69M$255.33M——
PP&E, net$63.66M$59.09M$53.80M$45.93M$40.38M$34.83M——
Total assets$347.36M$358.46M$379.34M$246.70M$266.30M$295.74M——
Current liabilities$48.27M$50.37M$42.93M$35.76M$32.26M$37.98M——
Long-term debt$72.50M$42.65M$42.26M$41.87M$41.49M$41.10M——
Total debt$72.50M$42.65M$42.26M$41.87M$41.49M$41.10M——
Total liabilities$125.00M$98.81M$91.35M$82.62M$82.14M$90.34M——
Shareholders' equity$222.36M$259.66M$287.99M$164.08M$184.16M$205.41M-$257.89M-$236.54M
Net debt$3.94M-$57.06M-$249.06M-$133.55M-$159.73M-$196.83M——
Shares outstanding59.27M58.38M58.35M51.45M51.35M51.35M100—
Cash flow statement
Operating cash flow-$32.30M-$18.72M-$18.37M-$18.34M-$26.27M-$24.06M-$18.00M-$18.06M
Capital expenditure$8.34M$9.66M$9.80M$7.26M$8.17M$7.39M$4.06M$4.45M
Free cash flow-$40.63M-$28.38M-$28.16M-$25.61M-$34.44M-$31.45M-$22.06M-$22.50M
Investing cash flow-$21.35M-$172.71M-$14.92M-$7.42M-$8.23M-$7.40M-$4.45M-$4.42M
Financing cash flow$22.50M-$185,000$149.18M-$27,000-$1.88M$214.70M-$119,000-$575,000
Depreciation & amortization$2.66M$2.33M$1.98M$2.37M$2.03M$1.84M$1.89M$1.87M
Stock-based compensation$9.52M$10.30M$10.11M$8.65M$4.58M$22.31M$459,000$1.12M

Free plan shows the latest 8 periods; Pro shows all 9 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.